Drug Development

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.